FindTrial
Sign In

The Efficacies and Safeties of a 0.05% Cyclosporine Nanoemulsion and a 0.1% Cyclosporine Cationic Emulsion

The Efficacies and Safeties of a 0.05% Cyclosporine Nanoemulsion and a 0.1% Cyclosporine Cationic Emulsion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007916
Enrollment
20
Registered
2022-11-18
Start date
2020-01-28
Completion date
Unknown
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Kangbuk Samsung Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. age above 19 years 2. Patients diagnosed with moderate to severe dray eye disease - ocular staining score = 3 or - TBUT =10 sec 3. possible to follow-up more than 3 monts 4. the patient who agree to participate in the study voluntarily

Exclusion criteria

Exclusion criteria: 1. patients using cyclosporine or used within 1 month 2. patients with active ocular infection such as Stevens-Johnson syndrome 3. history of corneal transplantation or neurotrophic keratitis 4. patients with ocular disease which can affect the result of study 5. patients with allergic reaction to cyclosporine

Design outcomes

Primary

MeasureTime frame
Efficacy of 0.05% cyclosporine Nanoemulsion—

Secondary

MeasureTime frame
TBUT, NEI scale, Schirmer test—

Countries

Korea, Republic of

Contacts

Public ContactSeong-Jae Kim

Gyeongsang National University Hospital

maya12kim@naver.com+82-55-750-8401

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026